TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14748937

Group type: EXPERIMENTAL
Intervention: High-protein, high-sodium diet (90 g/d protein, 180 mmol/d Na)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Basal diet (70 g/d protein, 65 mmol/d Na)
Number of subjects: 24
Study: 11167954

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 3722

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3722
Study: 9606842

Group type: EXPERIMENTAL
Intervention: Antithrombin III
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Protein C
Number of subjects: 4

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 4
Study: 7939431

Group type: COMPARATOR
Intervention: Oral teicoplanin 100 mg twice daily for 7 days (BID group)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Oral teicoplanin 50 mg 4 times daily for 3 days, followed by 100 mg twice daily for 4 days (QID group)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: QID group
Number of subjects: 92
Study: 3283457

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with tamoxifen
Number of subjects: 539

Group type: COMPARATOR
Intervention: No adjuvant tamoxifen
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Receptor-positive tumors
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Receptor-negative tumors
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Postmenopausal patients
Number of subjects: 539
Study: 29365125

Group type: EXPERIMENTAL
Intervention: Pentatherapy (darunavir/ritonavir, tenofovir disoproxil fumarate/emtricitabine, raltegravir, and maraviroc)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tritherapy (darunavir/ritonavir, tenofovir disoproxil fumarate, and emtricitabine)
Number of subjects: 50
Study: 27079708

Group type: EXPERIMENTAL
Intervention: Kirtan Kriya Meditation (KK)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Music Listening (ML)
Number of subjects: 60
Study: 24760352

Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3.1% sodium chloride solution (hypertonic saline)
Number of subjects: 0
Study: 23107971

Group type: COMPARATOR
Intervention: Standard dose gemcitabine (1,000 mg/m2) with carboplatin (AUC 5)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose prolonged infusion gemcitabine (350 mg/m2) with carboplatin (AUC 5)
Number of subjects: 60
Study: 20122038

Group type: EXPERIMENTAL
Intervention: REACH intervention (individual risk profiles, nine in-home sessions, three telephone sessions over 6 months)
Number of subjects: 495

Group type: COMPARATOR
Intervention: No-treatment control group (two brief 'check-in' telephone calls during 6 months)
Number of subjects: 495
Study: 18310162

Group type: EXPERIMENTAL
Intervention: Computerized physician order entry (CPOE)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Control (pre-implementation of CPOE)
Number of subjects: 627
Study: 15802773

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bisphosphonates
Number of subjects: 0
Study: 12592896

Group type: EXPERIMENTAL
Intervention: General carbon dioxide baths and therapeutic exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10235192

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg, clarithromycin 500 mg, and amoxicillin 1 g, all given b.i.d. for 10 days
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate, amoxicillin, and clarithromycin (10-day therapy)
Number of subjects: 77
Study: 8557125

Group type: EXPERIMENTAL
Intervention: Agonist administered irrespective of cycle phase
Number of subjects: 557
Study: 1758931

Group type: EXPERIMENTAL
Intervention: Tonic water plus vodka (approximately .05% blood alcohol level)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tonic water only
Number of subjects: 40
Study: 7078423

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 5 mg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 30442422

Group type: COMPARATOR
Intervention: Female caregivers
Number of subjects: 13
Study: 28359339

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg for 2 weeks before surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: No change to current statin therapy
Number of subjects: 30
Study: 26180476

Group type: EXPERIMENTAL
Intervention: Hinged posterior YAG capsulotomy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional circular YAG capsulotomy
Number of subjects: 83
Study: 25113389

Group type: EXPERIMENTAL
Intervention: 3D strain analysis
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2D and 3D strain analysis
Number of subjects: 50
Study: 22015451

Group type: EXPERIMENTAL
Intervention: Single-dose rasburicase (0.15 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Daily dosing of rasburicase for 5 days
Number of subjects: 80
Study: 19509098

Group type: EXPERIMENTAL
Intervention: Clomiphene, metformin, or combination of both for up to six cycles
Number of subjects: 626
Study: 17244248

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2a monotherapy (9 MUI/day for 4 weeks and then 3 MUI/3 t.i.w. for 44 weeks)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2a + Amantadine (100 mg twice daily for 48 weeks)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2a + Ribavirin (1000-1200 mg)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2a + Amantadine + Ribavirin
Number of subjects: 378
Study: 15195760

Group type: EXPERIMENTAL
Intervention: c‐PET system
Number of subjects: 74

Group type: COMPARATOR
Intervention: d‐PET system
Number of subjects: 74
Study: 12271419

Group type: EXPERIMENTAL
Intervention: (99m)Tc-sestamibi/(18)F-FDG DISA SPET
Number of subjects: 19

Group type: COMPARATOR
Intervention: (13)N-ammonia/(18)F-FDG PET
Number of subjects: 19
Study: 9830234

Group type: EXPERIMENTAL
Intervention: Controlled-release 5-ISMN 60 mg once daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional 5-ISMN 20 mg twice daily
Number of subjects: 44
Study: 8132132

Group type: EXPERIMENTAL
Intervention: Melatonin (2 to 10mg oral, given at bedtime)
Number of subjects: 15
Study: 3777565

Group type: EXPERIMENTAL
Intervention: Bolus method (Group A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Continuous infusion method (Group B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 16
Study: 29571808

Group type: EXPERIMENTAL
Intervention: Dual-energy CTPA (Group 1: 80/Sn140 kVp, 89/38 mAs)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dual-energy CTPA (Group 2: 100/Sn140 kVp, 89/76 mAs)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Single-energy CTPA (Group 3: 120 kVp, 110 mAs)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Dual-energy CTPA (Group 1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Single-energy CTPA (Group 3)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Dual-energy CTPA (Group 2)
Number of subjects: 62
Study: 27112909

Group type: EXPERIMENTAL
Intervention: Brief video (BV)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: CCO-CPR class
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control (sham video)
Number of subjects: 179
Study: 24851689

Group type: COMPARATOR
Intervention: PCV‐VG group
Number of subjects: 30
Study: 22612306

Group type: EXPERIMENTAL
Intervention: MBSCT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: NTX
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: NTX + MBSCT
Number of subjects: 200
Study: 20657853

Group type: EXPERIMENTAL
Intervention: Bismuth subgallate paste
Number of subjects: 10

Group type: COMPARATOR
Intervention: Moistened gauze pressure
Number of subjects: 10
Study: 18562775

Group type: EXPERIMENTAL
Intervention: High-GI/High-GL meal (H-H) - Carbohydrate content 65%, GI 79, GL 82
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-GI/Low-GL meal (L-L) - Carbohydrate content 65%, GI 40, GL 42
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-GI/Low-GL meal (H-L) - Carbohydrate content 36%, GI 78, GL 44
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study: 18401016

Group type: EXPERIMENTAL
Intervention: 852A 0.01%
Number of subjects: 32

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 852A 0.1%
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 852A 0.3%
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 852A 1.0%
Number of subjects: 32
Study: 12972438

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 13
Study: 11300437

Group type: EXPERIMENTAL
Intervention: Short hospital stay (3 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard hospital stay
Number of subjects: 120
Study: 9075595

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor-based treatment
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Diuretic-based treatment
Number of subjects: 6000
Study: 8104964

Group type: EXPERIMENTAL
Intervention: Lormetazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3530834

Group type: EXPERIMENTAL
Intervention: 1% ciclopirox olamine cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% clotrimazole cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cream vehicle
Number of subjects: 0
Study: 28301438

Group type: EXPERIMENTAL
Intervention: 12-week low-volume high-intensity interval training (HIIT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Low-moderate-intensity continuous training (Control Group)
Number of subjects: 90
Study: 29874567

Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fecal microbiome transplantation from mice on IF
Number of subjects: 0
Study: 27329657

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg intravenous at 0, 2, and 6 weeks)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Ciclosporin (2 mg/kg/day intravenous for 7 days followed by 5.5 mg/kg/day oral until 12 weeks)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 270

Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 270
Study: 24576533

Group type: EXPERIMENTAL
Intervention: Haloperidol (1mg/kg)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (various)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 263
Study: 22105061

Group type: EXPERIMENTAL
Intervention: Buprenorphine therapy in an opioid treatment program (OTP) with individual counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine therapy in a group counseling program utilizing the Matrix Model (MMM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine therapy in a private clinic setting mirroring standard medical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buprenorphine treatment
Number of subjects: 0
Study: 19757225

Group type: EXPERIMENTAL
Intervention: Visual imagery technique
Number of subjects: 153

Group type: COMPARATOR
Intervention: Active control (relaxation training and general imagery techniques)
Number of subjects: 153

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 153
Study: 17452229

Group type: EXPERIMENTAL
Intervention: Nasal intermittent mandatory ventilation (NIMV)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 84
Study: 15768813

Group type: EXPERIMENTAL
Intervention: 100 mg/l topical amphotericin B
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 50 mg/l topical amphotericin B
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 41
Study: 11486703

Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G‐CSF)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 9738066

Group type: EXPERIMENTAL
Intervention: BHI-VAN broth (brain heart infusion broth, horse serum, and yeast extract supplemented with vancomycin, amphotericin B, and nalidixic acid)
Number of subjects: 254
Study: 7809438

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 53
Study: 3046382

Group type: EXPERIMENTAL
Intervention: S‐adenosylmethionine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Imipramine (low oral doses)
Number of subjects: 18
Study: 30521521

Group type: EXPERIMENTAL
Intervention: Tailored multifaceted implementation strategy (local action planning, education and training, feedback on performance, lumbar puncture pack, optional components)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups (pre-intervention comparison)
Number of subjects: 489
Study: 27611311

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) patches
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 1050
Study: 25624196

Group type: EXPERIMENTAL
Intervention: Long GnRH agonist cycles
Number of subjects: 1205

Group type: EXPERIMENTAL
Intervention: GnRH antagonist cycles
Number of subjects: 1205
Study: 22769438

Group type: EXPERIMENTAL
Intervention: Open-flap debridement (OFD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Open-flap debridement in endodontically treated teeth (OFD + ET)
Number of subjects: 60
Study: 21127273

Group type: EXPERIMENTAL
Intervention: Sartorius muscle stimulation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Quadriceps muscle stimulation
Number of subjects: 72
Study: 18756943

Group type: EXPERIMENTAL
Intervention: Activated carbon nanoparticles injection (either by endoscopic injection or intraoperative subserosal injection)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no activated carbon nanoparticles injection)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Activated carbon nanoparticles injection
Number of subjects: 42
Study: 17043255

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 80
Study: 11814098

Group type: EXPERIMENTAL
Intervention: Quotidian hemodialysis
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional hemodialysis
Number of subjects: 18
Study: 10037380

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for 1 month
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 40
Study: 7740908

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg midazolam
Number of subjects: 102

Group type: COMPARATOR
Intervention: Combination of meperidine 6.0 mg/mL, atropine 0.08 mg/mL, and diazepam 0.6 mg/mL (0.2 mL/kg)
Number of subjects: 102
Study: 2251993

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Anticoagulants (heparin followed by phenprocoumon)
Number of subjects: 235
Study: 7248206

Group type: EXPERIMENTAL
Intervention: Role rehearsal and modelling
Number of subjects: 51

Group type: COMPARATOR
Intervention: Guided discussion
Number of subjects: 51
Study: 30810785

Group type: EXPERIMENTAL
Intervention: Mobile-bearing (MB) TKA
Number of subjects: 393

Group type: COMPARATOR
Intervention: Fixed-bearing (FB) TKA
Number of subjects: 393
Study: 27538832

Group type: EXPERIMENTAL
Intervention: Balance and mobility training (BMT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Balance and mobility plus cognitive training (BMT + C)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 44
Study: 26418274

Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin administration
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 23233381

Group type: EXPERIMENTAL
Intervention: Proposed technique using NAV-rejected k-space lines
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional method using NAV-accepted lines
Number of subjects: 31

Group type: COMPARATOR
Intervention: Simple averaging of all k-space lines
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Proposed technique for late gadolinium enhancement
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional method for late gadolinium enhancement
Number of subjects: 31

Group type: COMPARATOR
Intervention: Simple averaging for late gadolinium enhancement
Number of subjects: 31
Study: 21209033

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 5000
Study: 19617841

Group type: EXPERIMENTAL
Intervention: Leg wrapping with tight elastic bandage plus placebo intravenous injections
Number of subjects: 40

Group type: COMPARATOR
Intervention: Repeated phenylephrine boluses of 50 microg plus loose placebo wrapping
Number of subjects: 40
Study: 17179052

Group type: EXPERIMENTAL
Intervention: Agalsidase beta (1 mg per kg of body weight) every 2 weeks for up to 35 months (median, 18.5 months)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Agalsidase beta (1 mg per kg of body weight) in protocol-adherent patients
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Agalsidase beta (1 mg per kg of body weight) in patients with baseline eGFR > 55 mL/min per 1.73 m2
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Agalsidase beta (1 mg per kg of body weight) in patients with baseline eGFR ≤ 55 mL/min per 1.73 m2
Number of subjects: 82

Group type: COMPARATOR
Intervention: Agalsidase beta and Placebo
Number of subjects: 82
Study: 15193468

Group type: EXPERIMENTAL
Intervention: Culture media with 5% carbon dioxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Culture media with 6% carbon dioxide
Number of subjects: 0
Study: 11531899

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Alniditan 1.4 mg
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Alniditan 1.8 mg
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg
Number of subjects: 924
Study: 9471290

Group type: EXPERIMENTAL
Intervention: EMLA cream (lidocaine and prilocaine) applied before laser treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: No local anesthesia (control group)
Number of subjects: 6
Study: 8509530

Group type: EXPERIMENTAL
Intervention: Single-stage tilt test with an infusion of 5 micrograms/min of isoproterenol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Multistage tilt test with infusions of 0, 2 and 5 micrograms/min of isoproterenol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single-stage tilt test
Number of subjects: 40

Group type: COMPARATOR
Intervention: Multistage tilt test
Number of subjects: 40
Study: 3543769

Group type: EXPERIMENTAL
Intervention: Mezlocillin (4 g intravenously before surgery, second dose 4-6 hours later, final dose 6 hours after)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline, same dosing schedule as mezlocillin)
Number of subjects: 30
Study: 31272592

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 52
Study: 27605214

Group type: EXPERIMENTAL
Intervention: Telephone-based health coaching
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study: 26048382

Group type: EXPERIMENTAL
Intervention: Nicorandil (infused in addition to saline for 4 hours before and 24 hours after PCI)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 213
Study: 23787458

Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL) treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (nontreated patients with keratoconus)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: CXL treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 21490140

Group type: EXPERIMENTAL
Intervention: DHA-rich fish-oil capsules (≈800 mg DHA/d)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Vegetable oil capsules (control group)
Number of subjects: 182
Study: 19190915

Group type: EXPERIMENTAL
Intervention: Patients with severe tricuspid AS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Controls (without valvular pathology)
Number of subjects: 100
Study: 16763099

Group type: EXPERIMENTAL
Intervention: Low intensity exercise (Lo) at 39 +/- 3% peak oxygen consumption for 60 min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High intensity exercise (Hi) at 83 +/- 2% peak oxygen consumption for 27 +/- 2 min
Number of subjects: 6

Group type: COMPARATOR
Intervention: Both exercise intensities (Lo and Hi)
Number of subjects: 6
Study: 15221297

Group type: EXPERIMENTAL
Intervention: Group A (TIMI flow 2-3)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36

Group type: COMPARATOR
Intervention: Group B (TIMI flow 0-1)
Number of subjects: 36
Study: 10761206

Group type: EXPERIMENTAL
Intervention: Combination therapy (isosorbide‐5‐mononitrate and propranolol or nadolol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol or nadolol alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emergency sclerotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy and endoscopic banding ligation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacological therapy followed by semi‐emergency endoscopic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TIPS or emergency surgery
Number of subjects: 0
Study: 8383415

Group type: EXPERIMENTAL
Intervention: 18 mg iron daily
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 100 mg iron daily
Number of subjects: 43
Study: 3532848

Group type: EXPERIMENTAL
Intervention: Radiolabeled synthetic oligonucleotide probe
Number of subjects: 50
Study: 2463726

Group type: EXPERIMENTAL
Intervention: Dextran 40 (n = 16)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Acetated Ringer solution (n = 45)
Number of subjects: 61
Study: 30830708

Group type: EXPERIMENTAL
Intervention: Nurses' empathy motivation scale (27 items) validated through psychometric evaluation
Number of subjects: 640